What are potential risks of long-term proton pump inhibitor use and how should monitoring be influenced?

• A. Nutrient deficiencies (B12, Mg), C. diff infection, osteoporosis; reassess need for therapy and consider stepping down.
• B. Increased risk of hypertension and hyperglycemia; no changes to monitoring.
• C. No significant risks; continue therapy indefinitely with no reassessment.
• D. Only risk is kidney stones; monitor renal function exclusively.

Answer: (A)

Long-term proton pump inhibitor use changes the stomach’s acidic environment, which can affect how nutrients are absorbed and how the gut flora protect against infections. This raises several potential risks: vitamin B12 deficiency from reduced acid needed to release B12 from food, magnesium deficiency with prolonged use, and an increased risk of osteoporosis and fractures due to impaired calcium absorption and other effects on bone metabolism. The less acidic gut can also permit organisms such as Clostridioides difficile to thrive, increasing the chance of C. difficile infection.

Because these risks exist, monitoring should be guided by a strategy to minimize exposure while preserving symptom control. Reassess the ongoing need for therapy at regular intervals, aim for the lowest effective dose, and consider stepping down or discontinuing the PPI when feasible. For nutrient issues, monitor for signs of deficiency and consider laboratory checks (for example, B12 status and magnesium if symptoms or risk factors are present). For bone health, evaluate fracture risk and bone density when indicated and ensure adequate calcium and vitamin D, along with lifestyle measures that support bone health. Be vigilant for signs of C. difficile infection, such as new-onset diarrhea, and evaluate appropriately.

Other options don’t align with the evidence: risks like hypertension or hyperglycemia aren’t established primary concerns with long-term PPI use, and suggesting no need for monitoring ignores documented nutritional and infection risks. The idea that there are no significant risks or that only one narrow issue (like kidney stones) would necessitate exclusive renal monitoring also misses the broader set of potential problems and the need for reassessment and dose optimization.